The International Journal of Stroke is the flagship publication of the World Stroke Organization (WSO). Within a very brief period of time the WSO has clearly established itself as the lead stroke organization globally. The WSO focus on education and the promotion of research worldwide has made it a key collaborator with the World Health Organization (WHO). Moving stroke from under the cardiovascular umbrella and into the neurosciences within the WHO, presents a unique opportunity to focus on stroke specific problems, ranging from prevention right through to rehabilitation and community management. Do not underestimate the significance of this classification change as funding often follows WHO activities. As a stand-alone disease of such significant global burden within the neurosciences, the opportunities ahead must be firmly grasped! Why should you support the WSO? Primarily, a large professional membership will lend considerable weight to the argument that researchers are serious about reducing the burden of stroke, globally.
And secondarily, as the second most common cause of death worldwide, a proportional number of concerned investigators and clinicians should band together under the unified umbrella of the WSO. These are altruistic reasons for joining, and should be the primary driver for professionals becoming a member; however, there are also more practical and immediate benefits in being a WSO member, these include: With your support the WSO can be your advocate for change in systems worldwide, helping to prevent, acutely treat, and rehabilitate stroke globally.
In this issue we draw attention to the impending Warfarin wars with a provocative Leading opinion article by Hans-Christoph Diener et al. The analogy drawn with the Diadoch wars is most appropriate; we are in the fascinating position of having a change of the therapeutic guard for the first time in 50 years, with a tense struggle among a number of potential successors. We will all watch with interest and, no doubt to a certain degree participate. The beneficiaries of course, will be people today who will not have a stroke due to the introduction of these significantly better therapeutic agents.
Interestingly, Yun-Fang Tsai et al, have provided data to illustrate the underuse of anticoagulants in patients with AF, particularly to parts of Asia. It seems likely that the Warfarin wars will result in a reversal of this unfortunate state of affairs.
Of course we have other articles of interest as always! Remember supporting the WSO supports our journal: the accessible voice of stroke internationally.
